Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.

Aliment Pharmacol Ther · 2015 · PMC5014135 · PMID 26201312

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Among those with severe grades C/D, the proportion of healed EO subjects was numerically higher after 4‐week treatment with VPZ20 (100%) or VPZ40 (96.0%) than after 4‐week treatment with VPZ5 (87.3%), VPZ10 (86.4%) or LPZ30 (87.0%), although these differences did not reach statistical significance.

also in 111,027 other papers

a decreasing trendno p-value reported

Assessment of the mean severity score of all EO‐related symptoms on the basis of entries in the patient's diaries revealed a decreasing trend in all treatment groups but no significant differences between the groups (Table 5 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.